Probucol-induced hypocholesterolemia is not associated with exacerbated foam cell formation in ABCG1 knockout mice

We have recently published in Atherosclerosis that the regression capacity of established atherosclerotic lesions is diminished by treatment of mice with the lipid-lowering drug probucol [1]. Yamamoto et al. have shown that probucol treatment in wild-type mice does not diminish the flux of cholesterol from lipid-laden macrophages back to the liver and feces (reverse cholesterol transport) [2]. We thus anticipated that the probucol effect was primarily related to lowering of plasma high-density lipoprotein (HDL) levels, resulting from the disruption of ATP-binding cassette transporter A1 (ABCA1) function in hepatocytes.
Source: Atherosclerosis - Category: Cardiology Authors: Tags: Correspondence Source Type: research